Hua Jing, Zhang Xin, Wang Na, Ran Linyu, Wang Shengyun, Huang Chiungwei, Gao Wei, Qian Chenchen, Guo Wei, Liu Zhongmin, Li Qiang, Wang Feilong
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Kunming, China.
Front Med (Lausanne). 2021 Nov 12;8:697338. doi: 10.3389/fmed.2021.697338. eCollection 2021.
Covid-19, Coronavirus disease 2019; ARDS, Acute respiratory distress syndrome; ECMO, Extracorporeal Membrane Oxygenation; WHO, World Health Organization; ICUs, Intensive care units. Acute respiratory distress syndrome (ARDS) is a fatal comorbidity of critically ill patients with COVID-19, who often end up on respiratory support. However, the safety and effectiveness of Extracorporeal Membrane Oxygenation (ECMO) in the treatment of COVID-19 remains to be elucidated at present. Here, we report on nine patients who received ECMO due to severe SARS-CoV-2 infection in Wuhan, China. Our initial experiences suggest that carefully selecting patients, as well as management by a well-trained team, are critical to implementing ECMO in patients with COVID-19. More randomized controlled trials with larger sample sizes are needed to evaluate the usefulness of ECMO in patients with COVID-19.
新型冠状病毒肺炎（COVID-19）、2019冠状病毒病；急性呼吸窘迫综合征（ARDS）；体外膜肺氧合（ECMO）；世界卫生组织（WHO）；重症监护病房（ICUs）。急性呼吸窘迫综合征（ARDS）是COVID-19重症患者的一种致命合并症，这些患者最终往往需要呼吸支持。然而，体外膜肺氧合（ECMO）治疗COVID-19的安全性和有效性目前仍有待阐明。在此，我们报告了在中国武汉因严重SARS-CoV-2感染接受ECMO治疗的9例患者。我们的初步经验表明，仔细挑选患者以及由训练有素的团队进行管理，对于在COVID-19患者中实施ECMO至关重要。需要更多样本量更大的随机对照试验来评估ECMO在COVID-19患者中的效用。
